250 related articles for article (PubMed ID: 21992533)
21. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
Martin ST; Powell JT; Patel M; Tsapepas D
Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
[TBL] [Abstract][Full Text] [Related]
22. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials.
Schnitzler MA; Lentine KL; Axelrod D; Gheorghian A; You M; Kalsekar A; L'Italien G
Transplantation; 2012 Jan; 93(2):172-81. PubMed ID: 22198496
[TBL] [Abstract][Full Text] [Related]
23. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.
Klintmalm GB; Feng S; Lake JR; Vargas HE; Wekerle T; Agnes S; Brown KA; Nashan B; Rostaing L; Meadows-Shropshire S; Agarwal M; Harler MB; Garcia-Valdecasas JC
Am J Transplant; 2014 Aug; 14(8):1817-27. PubMed ID: 25041339
[TBL] [Abstract][Full Text] [Related]
24. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
[TBL] [Abstract][Full Text] [Related]
25. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
26. Belatacept in kidney transplantation.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
[TBL] [Abstract][Full Text] [Related]
27. Projecting long-term graft and patient survival after transplantation.
Levy AR; Briggs AH; Johnston K; MacLean JR; Yuan Y; L'Italien GJ; Kalsekar A; Schnitzler MA
Value Health; 2014 Mar; 17(2):254-60. PubMed ID: 24636384
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant.
Florman S; Becker T; Bresnahan B; Chevaile-Ramos A; Carvalho D; Grannas G; Muehlbacher F; O'Connell PJ; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2017 Jan; 17(1):180-190. PubMed ID: 27232116
[TBL] [Abstract][Full Text] [Related]
29. Does belatacept improve outcomes for kidney transplant recipients? A systematic review.
Talawila N; Pengel LH
Transpl Int; 2015 Nov; 28(11):1251-64. PubMed ID: 25965549
[TBL] [Abstract][Full Text] [Related]
30. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2010 Dec; 15(6):697-702. PubMed ID: 20930638
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
[TBL] [Abstract][Full Text] [Related]
32. Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A.
Furuzawa-Carballeda J; Lima G; Alberú J; Palafox D; Uribe-Uribe N; Morales-Buenrostro LE; Reyes Acevedo R; Mondragón G; Chevaile A; Llorente L
Clin Exp Immunol; 2012 Feb; 167(2):330-7. PubMed ID: 22236010
[TBL] [Abstract][Full Text] [Related]
33. Costimulation blockade with belatacept in renal transplantation.
Vincenti F; Larsen C; Durrbach A; Wekerle T; Nashan B; Blancho G; Lang P; Grinyo J; Halloran PF; Solez K; Hagerty D; Levy E; Zhou W; Natarajan K; Charpentier B;
N Engl J Med; 2005 Aug; 353(8):770-81. PubMed ID: 16120857
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
35. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
36. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
37. Belatacept: the promises and challenges of belatacept and costimulatory blockade.
Kaplan B
Am J Transplant; 2010 Mar; 10(3):441-2. PubMed ID: 20415895
[TBL] [Abstract][Full Text] [Related]
38. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials.
Lange NW; King K; Husain SA; Salerno DM; Tsapepas DS; Hedvat J; Yu M; Mohan S
Am J Transplant; 2024 Jun; 24(6):1027-1034. PubMed ID: 38387620
[TBL] [Abstract][Full Text] [Related]
39. Five-year safety and efficacy of belatacept in renal transplantation.
Vincenti F; Blancho G; Durrbach A; Friend P; Grinyo J; Halloran PF; Klempnauer J; Lang P; Larsen CP; Mühlbacher F; Nashan B; Soulillou JP; Vanrenterghem Y; Wekerle T; Agarwal M; Gujrathi S; Shen J; Shi R; Townsend R; Charpentier B
J Am Soc Nephrol; 2010 Sep; 21(9):1587-96. PubMed ID: 20634298
[TBL] [Abstract][Full Text] [Related]
40. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
